Victory Capital Management Inc. raised its stake in shares of Revvity, Inc. (NYSE:RVTY – Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 59,860 shares of the company’s stock after acquiring an additional 2,582 shares during the period. Victory Capital Management Inc.’s holdings in Revvity were worth $7,647,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of RVTY. Rothschild Investment LLC acquired a new position in Revvity during the second quarter worth about $25,000. EverSource Wealth Advisors LLC grew its position in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after purchasing an additional 167 shares during the last quarter. Fairfield Financial Advisors LTD purchased a new position in shares of Revvity during the 2nd quarter worth approximately $43,000. Family Firm Inc. purchased a new stake in Revvity in the 2nd quarter valued at approximately $43,000. Finally, EntryPoint Capital LLC acquired a new stake in Revvity during the 1st quarter valued at $48,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, insider Tajinder S. Vohra sold 2,154 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares in the company, valued at $2,392,237.96. This trade represents a 9.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.60% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Analysis on Revvity
Revvity Stock Performance
Shares of NYSE RVTY opened at $111.11 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. The stock has a 50 day moving average price of $120.91 and a 200 day moving average price of $115.53. Revvity, Inc. has a 52 week low of $86.30 and a 52 week high of $129.50. The stock has a market capitalization of $13.52 billion, a PE ratio of 53.68, a price-to-earnings-growth ratio of 2.74 and a beta of 1.05.
Revvity (NYSE:RVTY – Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The business had revenue of $684.10 million for the quarter, compared to analyst estimates of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. Revvity’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Analysts predict that Revvity, Inc. will post 4.85 earnings per share for the current fiscal year.
Revvity declared that its board has approved a stock buyback program on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 6.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
Revvity Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s dividend payout ratio (DPR) is presently 13.53%.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
- Five stocks we like better than Revvity
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.